- Home
- ADAP vs RLYB Comparison
ADAP vs RLYB Comparison
Compare ADAP & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- RLYB
- Stock Information
- Founded
- ADAP 2008
- RLYB 2018
- Country
- ADAP United Kingdom
- RLYB United States
- Employees
- ADAP N/A
- RLYB N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- ADAP Health Care
- RLYB Health Care
- Exchange
- ADAP Nasdaq
- RLYB Nasdaq
- Market Cap
- ADAP 21.3M
- RLYB 24.1M
- IPO Year
- ADAP 2015
- RLYB 2021
- Fundamental
- Price
- ADAP $0.07
- RLYB $0.59
- Analyst Decision
- ADAP Hold
- RLYB Hold
- Analyst Count
- ADAP 6
- RLYB 2
- Target Price
- ADAP $1.02
- RLYB N/A
- AVG Volume (30 Days)
- ADAP 63.5M
- RLYB 385.4K
- Earning Date
- ADAP 11-12-2025
- RLYB 11-06-2025
- Dividend Yield
- ADAP N/A
- RLYB N/A
- EPS Growth
- ADAP N/A
- RLYB N/A
- EPS
- ADAP N/A
- RLYB N/A
- Revenue
- ADAP $65,084,999.00
- RLYB $761,000.00
- Revenue This Year
- ADAP N/A
- RLYB N/A
- Revenue Next Year
- ADAP $52.35
- RLYB N/A
- P/E Ratio
- ADAP N/A
- RLYB N/A
- Revenue Growth
- ADAP N/A
- RLYB 154.51
- 52 Week Low
- ADAP $0.04
- RLYB $0.22
- 52 Week High
- ADAP $1.12
- RLYB $1.24
- Technical
- Relative Strength Index (RSI)
- ADAP 44.99
- RLYB 55.28
- Support Level
- ADAP $0.06
- RLYB $0.58
- Resistance Level
- ADAP $0.07
- RLYB $0.61
- Average True Range (ATR)
- ADAP 0.01
- RLYB 0.04
- MACD
- ADAP 0.01
- RLYB -0.00
- Stochastic Oscillator
- ADAP 88.67
- RLYB 73.86
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.